FDA approves new single tablet HIV treatment

Share this article:
The FDA yesterday approved Bristol-Myers Squibb’s and Gilead Sciences Atripla, the first ever once-a-day single tablet regiment to treat HIV as a stand-alone therapy or in combination with other retrovirals. It is the first AIDS treatment to mix drugs made by different manufacturers. Atripla combines Bristol-Myers Squibb’s Sustiva, and Gilead’s Truvada and will be available in the US within seven business days, the companies said. The two companies established their joint venture to develop and commercialize Atripla in December 2004.s The FDA cleared the Atripla in less than three months as part of a push to introduce treatments that combine already-approved HIV drugs.
Share this article:
You must be a registered member of MMM to post a comment.


Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.